Parkwood LLC maintained its stake in KemPharm, Inc. (NASDAQ:KMPH) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 125,809 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Parkwood LLC owned about 0.86% of KemPharm worth $503,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Creative Planning boosted its stake in KemPharm by 2.3% in the first quarter. Creative Planning now owns 453,723 shares of the specialty pharmaceutical company’s stock valued at $2,223,000 after buying an additional 10,200 shares during the last quarter. C WorldWide Group Holding A S boosted its stake in KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock valued at $890,000 after buying an additional 16,699 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in KemPharm during the first quarter valued at approximately $647,000. Finally, Bank of New York Mellon Corp boosted its stake in KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares during the last quarter. 42.27% of the stock is owned by hedge funds and other institutional investors.
Shares of KemPharm, Inc. (NASDAQ KMPH) traded up 5.00% during mid-day trading on Friday, hitting $3.15. 46,796 shares of the stock traded hands. KemPharm, Inc. has a 52 week low of $2.90 and a 52 week high of $5.50. The stock has a 50-day moving average of $3.48 and a 200-day moving average of $3.92. The company’s market cap is $46.14 million.
KemPharm (NASDAQ:KMPH) last released its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. Analysts anticipate that KemPharm, Inc. will post ($2.80) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Parkwood LLC Has $503,000 Stake in KemPharm, Inc. (NASDAQ:KMPH)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/08/11/parkwood-llc-continues-to-hold-position-in-kempharm-inc-nasdaqkmph-updated.html.
KMPH has been the subject of several recent analyst reports. Zacks Investment Research cut shares of KemPharm from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Canaccord Genuity set a $7.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research note on Thursday. Oppenheimer Holdings, Inc. set a $13.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research note on Wednesday, May 10th. ValuEngine raised shares of KemPharm from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 1st. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $8.00 price objective on shares of KemPharm in a research note on Monday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. KemPharm has an average rating of “Buy” and an average price target of $8.10.
In related news, CEO Travis C. Mickle bought 8,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was bought at an average price of $3.45 per share, for a total transaction of $27,600.00. Following the transaction, the chief executive officer now directly owns 1,629,612 shares in the company, valued at $5,622,161.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders acquired 10,775 shares of company stock valued at $38,783. Insiders own 22.80% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
What are top analysts saying about KemPharm Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for KemPharm Inc. and related companies.